Ogivri

Ogivri Description

trastuzumab

Manufacturer:

Biocon

Distributor:

DKSH

Marketer:

Meda Pharma
Full Prescribing Info
Description
Each single-dose vial of Ogivri delivers 150 mg trastuzumab. Reconstitution with 7.2 mL of sterile water for injection (SWFI) yields a solution containing 21 mg/mL trastuzumab that delivers 150 mg trastuzumab, at a pH of approximately 6.
Each multiple-dose vial of Ogivri delivers 440 mg trastuzumab. Reconstitution with 20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing 21 mg/mL trastuzumab that delivers 20 mL (440 mg trastuzumab), at a pH of approximately 6.
If Ogivri is reconstituted with SWFI without preservative, the reconstituted solution is considered single-dose.
Excipients/Inactive Ingredients: L-histidine, L-histidine hydrochloride, Polyethylene glycol 3350/macrogol 3350, D-sorbitol.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in